Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01422486 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
A Phase 2 study, sponsored by Telik.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01422486 is a Phase 2 study that was terminated before completion, run by Telik. The registered enrollment target is 2 participants.
The verdict
NCT01422486, a Phase 2 study, was terminated before completion, sponsored by Telik.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Study TLK199.2107 is a multicenter, single arm, open-label Phase 2 study of oral ezatiostat (Telintra®) in patients with lenalidomide (Revlimid®) refractory or resistant, red blood cell (RBC) transfusion-dependent, Low to Intermediate-1 IPSS risk, del5q Myelodysplastic Syndrome (MDS).
Interventions
- DRUG ezatiostat hydrochloride (Telintra®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01422486
The ClinicalTrials.gov registry entry for NCT01422486 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ezatiostat hydrochloride (Telintra®) is the first listed.
NCT01422486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01422486 about?
NCT01422486 is a clinical study titled "Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome". Study TLK199.2107 is a multicenter, single arm, open-label Phase 2 study of oral ezatiostat (Telintra®) in patients with lenalidomide (Revlimid®) refractory or resistant, red blood cell (RBC) transfusion-dependent, Low to Intermediate-1 IPSS risk, del5q Myelodysplastic Syndrome (MDS).
What is the current status of trial NCT01422486?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2011-10. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01422486?
The interventions under investigation include: ezatiostat hydrochloride (Telintra®) (DRUG).
Who is sponsoring clinical trial NCT01422486?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.